Cyban has developed a next generation brain pulse monitor that advances the treatment of brain injuries by delivering reliable information continuously from the site of trauma to hospital discharge.
Our device reduces the need for invasive surgical procedures to provide accurate measurement of brain oxygen levels, delivering unprecedented brain oxygen monitoring in a user-friendly and non-invasive manner.
Delivering instant and continuous insights into the early detection of brain hypoxia enables Cyban to help reduce mortality and disability.
The device delivers accurate results quickly, to enable confident clinical care at every stage of the patient journey. This delivers valuable intelligence to intensive care and operating room staff who can improve the quality and efficiency of care provided to patients.
Reducing the need for invasive and costly surgical procedures enables hospitals to save costs and free up valuable resources.
By increasing diagnosis accuracy and accelerating treatment time, hospitals can reduce patient stays and improve patient outcomes simultaneously.
Our history
As a practicing clinician in an intensive care unit (ICU), Dr Barry Dixon saw the limitations of existing monitoring systems in detecting complications early enough to allow interventions to prevent permanent injury or death. Seeing the potential to improve patient outcomes, Dr Dixon set out to develop a novel solution to this problem. As a result, Cyban was born.
Existing brain oxygen monitoring techniques fail to reliably detect and report brain hypoxia in patients with acquired and traumatic brain injury. Consequently, treatment of brain hypoxia is delayed, often resulting in permanent disability or death for the patient.
Cyban’s medical device improves outcomes for patients with severe brain injury by providing non-invasive, continuous reporting of brain oxygen levels to allow early detection and more importantly, early intervention, to prevent brain hypoxia.This results in better patient outcomes, reduced length of stay in high cost ICU and lower overall brain monitoring costs.
